[{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Zhejiang Hisun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AD-35","moa":"Acetylcholinesterase (AChE)","graph1":"Neurology","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"ZTI-01","moa":"antibiotics (Streptomyces strains); phosphoro-derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"9","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Silence Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"SLN360","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Esperion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Esperion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Esperion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Wockhardt","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Milestone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Etripamil","moa":"coronary vasodilators (verapamil type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Milestone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Etripamil","moa":"coronary vasodilators (verapamil type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Milestone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Etripamil","moa":"coronary vasodilators (verapamil type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Effector Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Saniona","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"LGD-6972","moa":"Glucagon receptor (GCGR)","graph1":"Endocrinology","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"AVM Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"AVM0703","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"AVM Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"AVM0703","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"AiCuris","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"AiCuris","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tivantinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tivantinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tivantinib","moa":"Hepatocyte growth factor receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Shield Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin-beta-3 substrate","graph1":"Hematology","graph2":"Approved FDF","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Serum","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Silence Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"KBP Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor (MR)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Leadiant Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"131-I Tenatumomab","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Edgewise Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Edgewise Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Edgewise Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diazoxide","moa":"ABCC8(SUR1)\/KCNJ11(KIR6.2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"LIB003","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"LIB003","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"18-F FPIA","moa":"Pyruvate kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Forma Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Innocoll Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase IV","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Sirnaomics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta-1\/COX-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection, Powder","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Blue Earth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Healios K.K","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Multipotent Adult Progenitor Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Healios K.K","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Multipotent Adult Progenitor Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Vivus","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"VI-1121","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Genomind","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu BetaBart","moa":"CD276","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Medpace, Inc \/ Medpace, Inc"}]
Find Clinical Drug Pipeline Developments & Deals by Medpace, Inc
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
